Physician profile
Brian N Stone
NPI 1972913556
$6,509.27
in general payments reported to CMS, 2019-2025
39 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 94% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $428 · 2021: $683 · 2022: $555 · 2023: $1,067 · 2024: $1,333 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,177.49 | 2021-2025 | Rinvoq, Qulipta |
| Amgen INC. | $1,147.49 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $1,140.65 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $461.09 | 2019-2025 | Bimzelx, Cimzia |
| Trice Medical, INC. | $195.81 | 2021-2024 | |
| Sobi, INC | $191.95 | 2021-2025 | |
| Organon LLC | $148.76 | 2024-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $143.28 | 2021-2025 | Taltz |
| Mallinckrodt Enterprises LLC | $133.34 | 2019 | |
| Novo Nordisk INC | $120.01 | 2022 | |
| Neurocrine Biosciences, INC. | $114.30 | 2025 | |
| Acadia Pharmaceuticals INC | $107.99 | 2024 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $107.52 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $104.25 | 2020-2021 | |
| Antares Pharma, INC. | $100.51 | 2022-2023 | Nocdurna, Xyosted, Tlando |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.